Welcome to the LeimkühlerLab. We specialize in research and analysis in Myelofibrosis and related areas. Our group was formed in 2022 under the Department of Hematology and Stem Cell Transplantation at Uniklinikum Essen. Our focus includes myelofibrosis, a rare blood cancer where scar tissue replaces bone marrow, impairing blood production and often leading to rapid decline or acute leukemia. Stem cell transplantation offers a potential cure, yet many patients are deemed unfit for the procedure. Our research aims to understand myelofibrosis's origins and devise effective treatments. We investigate the cells responsible for bone marrow scarring and draw insights from stem cell therapy. Our goal is to develop safer, equally effective therapies for patients. Our research is in molecular genetics and cellular biology with practical clinical applications, driven by our direct involvement with patients. The quest to unravel myelofibrosis's complexities fuels our curiosity and underscores the importance of addressing unanswered questions. This intersection of science and patient care propels us forward in our pursuit of better treatments and improved outcomes for those affected by myelofibrosis.